World Journal of Urology

, Volume 31, Issue 2, pp 331–337 | Cite as

Intratumoral acetic acid injection eradicates human prostate cancer tumors in a murine model

  • Jasneet Singh Bhullar
  • Gokulakkrishna Subhas
  • Sushant Chaudhary
  • Boris Silberberg
  • Jacqueline Tilak
  • Milessa Decker
  • Vijay K. Mittal
Original Article

Abstract

Introduction

To treat localized prostate cancer without substantial morbidity, an ideal treatment would be an effective local therapy with minimal morbidity. Direct injections have been used to treat benign prostatic hyperplasia without major complications, but in limited cases. We evaluated the local oncotoxic effects of acetic acid in a prostate cancer xenograft murine model.

Materials and methods

PC3 and LNCaP human prostate cancer cell lines were used to grow subcutaneous tumors in SCID mice. For each cell line, 14 mice underwent intratumor injection with 25 % acetic acid (0.05 ml/100 cm3 of tumor) after the tumor was >300 mm3. Post-treatment one mouse/group was euthanized after 2 h, 24 h, 1 and 2 weeks; remaining mice (n = 10) were killed at 120 days. Control mice (8/group) were euthanized after they met the humane criteria for tumor burden and overall health.

Results

Tumor necrosis was noted immediately post-injection; by 24 h, ulceration and crusting of overlying skin were noted, which healed into scars by 23 ± 5 days. Histological examination showed tumor degeneration and necrosis with blood vessel obstruction. Ten treated mice in both groups survived for 120 days, which was much longer than the mean survival of PC3 (40 ± 9 days) and LNCaP (56 ± 10) control mice.

Conclusions

Direct injection of acetic acid successfully eradicated both tumors. This treatment option could potentially be used in humans for treatment of early localized prostate cancer and nonoperative management of locally advanced cases. This is the first report of successful local chemical therapy for prostate cancer.

Keywords

Acetic acid Intratumoral injection Human prostate cancer cell lines Prostate cancer Xenograft Murine model 

References

  1. 1.
    Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C, Baldassare J (2009) Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res 17(28):84CrossRefGoogle Scholar
  2. 2.
    Springate CM, Jackson JK, Gleave ME, Burt HM (2005) Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother Pharmacol 56(3):239–247PubMedCrossRefGoogle Scholar
  3. 3.
    Kim ED (2002) Ethanol injection for the treatment of benign prostatic hyperplasia. Curr Urol Rep 3(4):276–279PubMedCrossRefGoogle Scholar
  4. 4.
    Talwar GL, Pande SK (1966) Injection treatment of enlarged prostate. Br J Surg 53(5):421–427PubMedCrossRefGoogle Scholar
  5. 5.
    Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M, Gonzalez-Martin M, Castiñeiras J, Ballanger P, Teillac P, Rolo F, Baena V, Erdmann J, Mirone V (2004) Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46(4):496–501 Discussion 501-2PubMedCrossRefGoogle Scholar
  6. 6.
    Plante MK, Marks LS, Anderson R, Amling C, Rukstalis D, Badlani G, Getlin L, Vang E (2007) Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 177(3):1030–1035 (discussion 1035)PubMedCrossRefGoogle Scholar
  7. 7.
    Goya N, Ishikawa N, Ito F, Ryoji O, Tokumoto T, Toma H, Yamaguchi Y (1999) Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol 162(2):383–386PubMedCrossRefGoogle Scholar
  8. 8.
    Amano H, Goya N, Ryoji O, Yagisawa T, Nakazawa H, Toma H (2002) Ethanol injection therapy for locally invasive prostatic adenocarcinoma. Urology 59(5):771–772PubMedCrossRefGoogle Scholar
  9. 9.
    Goya N, Koga S, Tomizawa Y, Onitsuka S, Yamaguchi Y, Toma H (2007) Effects of direct injection of dehydrated ethanol on PC3 human prostate cancer cells in nude mice: preliminary study. Int J Urol 4(8):760–763CrossRefGoogle Scholar
  10. 10.
    Khan NA, Baerlocher MO, Owen RJ, Ho S, Kachura JR, Kee ST, Liu DM (2010) Ablative technologies in the management of patients with primary and secondary liver cancer: an overview. Can Assoc Radiol J 61(4):217–222PubMedCrossRefGoogle Scholar
  11. 11.
    Padma S, Martinie JB, Iannitti DA (2009) Liver tumor ablation: percutaneous and open approaches. J Surg Oncol 100(8):619–634PubMedCrossRefGoogle Scholar
  12. 12.
    Dahm P, Yeung LL, Chang SS, Cookson MS (2008) A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol 180(2):451–459 (discussion 460)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Jasneet Singh Bhullar
    • 1
  • Gokulakkrishna Subhas
    • 1
  • Sushant Chaudhary
    • 1
  • Boris Silberberg
    • 2
  • Jacqueline Tilak
    • 2
  • Milessa Decker
    • 2
  • Vijay K. Mittal
    • 1
  1. 1.Department of SurgeryProvidence Hospital & Medical CentersSouthfieldUSA
  2. 2.Department of Patient Care ResearchProvidence Hospital & Medical CentersSouthfieldUSA

Personalised recommendations